Cuban attributes the US’ high drug prices to PBMs—often considered the “middlemen” within the pharma supply chain—arguing ...
In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and ...
In the second part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory ...
In today’s Pharma Pulse, a structured exercise program is proven to manage persistent long COVID symptoms, while Regeneron ...
The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a ...
In the first part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and ...
The Health Data, Technology, and Interoperability (HTI-4) Final Rule aims to strengthen the nation’s health IT ecosystem by ...
Cencora—often known as being one of the “Big Three” wholesalers—is continuing to invest in its third-party logistics (3PL) ...
In today’s Pharma Pulse, Dr. Richard Pazdur retires from his CDER director role weeks after his appointment, and much more.
In today’s Pharma Pulse, Dr. Tracy Beth Høeg is named acting CDER director amidst high leadership turnover, promising modernization and transparency.
In policy news, the United States and the United Kingdom have reached a deal in principle to establish 0% tariffs on ...
Pharma Pulse: RSV Protection Wanes, AstraZeneca Invests Big, and Novo Nordisk Faces Pipeline Setback
A new Pharma Pulse briefing unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback